Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | CASP5 | P51878 | 2/20 | 0.48 |
| ▸ | CASP4 | P49662 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15334687 | 0.98 | SMN1; SMN2 (0.48) | CASP1CASP5CASP4HRH1SMN1; SMN2 | |
| SCHEMBL7833457 | 0.95 | CASP1 (0.44) | CASP1CASP5CASP4HRH1SMN1; SMN2 | |
| SCHEMBL2772556 | 0.87 | CASP1 (0.61) | CASP1CASP5CASP4KMT2AMAPT | |
| SCHEMBL10143602 | 0.86 | HRH4 (0.54) | CASP1CASP5CASP4HRH1ALDH1A1 | |
| SCHEMBL3410110 | 0.86 | HTT (0.51) | CASP1CASP5CASP4SMN1; SMN2USP2 | |
| SCHEMBL2771547 | 0.86 | CASP1 (0.59) | CASP1CASP5CASP4SMN1; SMN2MAPT | |
| SCHEMBL29826722 | 0.86 | HTT (0.51) | CASP1CASP5CASP4SMN1; SMN2USP2 | |
| SCHEMBL3409761 | 0.84 | HTT (0.50) | SMN1; SMN2USP2HSD17B10MEN1HTT | |
| SCHEMBL10143604 | 0.84 | HRH4 (0.53) | CASP1CASP5CASP4SMN1; SMN2USP2 | |
| SCHEMBL2773410 | 0.83 | CASP1 (0.56) | CASP1CASP5CASP4KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023278483-A1 | COMPOUNDS HAVING 1H-PYRAZOLO[4,3-C]PYRIDIN-6-AMINOS AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278483-A1 | COMPOUNDS HAVING 1H-PYRAZOLO[4,3-C]PYRIDIN-6-AMINOS AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-6030976-A | SELECTIVE AFFINITY TO 5HT-6 RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER'S DISEASE, PSYCHOSES, SCHIZOPHRENIA, MANIC DEPRESSIONS, MEMORY DISORDERS, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS AND HUNTINGTON'S DISEASE | HOFFMAN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5998665-A | THERAPY FOR NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5939451-A | INDOL-4-YL-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5932599-A | 4-AMINO-N-(PYRIDINYL-4-YL)-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0815861-A1 | Sulphonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| US-5550240-A | Piperazinyl-bis(alkylamino)pyrimidine derivatives and process for preparing same | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1996-08-27 | — | — | US | disclosed |
| EP-0644885-A1 | NOVEL BIOLOGICALLY ACTIVE EBURNAMENINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | RICHETER GEDEON VEGYESZETI GYAR RT. (HU) | 1995-03-29 | — | — | EP | disclosed |
| EP-0644882-A1 | NOVEL PIPERZINYL-BIS(ALKYLAMINO)PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING SAME | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1995-03-29 | — | — | EP | disclosed |
| WO-1993025550-A1 | NOVEL BIOLOGICALLY ACTIVE EBURNAMENINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | RICHETER GEDEON VEGYÉSZETI GYÁR RT. (HU) | 1993-12-23 | — | — | WO | disclosed |
| WO-1993025539-A1 | NOVEL PIPERZINYL-BIS(ALKYLAMINO)PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | CASP1 2591/4885CASP5 1764/4885CASP4 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.